Shared on 30 Oct 25
Fair value Decreased 8.11%Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.
Loading...
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
28 Apr 25
Updated
30 Oct 25
AnalystConsensusTarget's Fair Value
US$6.80
67.5% undervalued intrinsic discount30 Oct
US$2.21
1Y
30.8%7D
-27.1%1Y
30.8%7D
-27.1%You can edit this narrative until Oct 31 10:05 PM. Then, changes will post as Updates.